Latest Europe News

Kuniko Limited has advanced exploration at its Commonwealth Gold–Silver Project in NSW, completing key surveys and securing approvals ahead of a planned diamond drilling campaign in February 2026. Meanwhile, its Nordic battery metals portfolio remains strategically positioned for future development.

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Evion Group gains momentum as the US-Africa Strategic Infrastructure and Investment Working Group fosters trade, Madagascar accelerates mining permits, and Indian graphite operations deliver strong sales.

Kingsrose Mining’s December quarter report reveals steady progress in its Finnmark exploration alliance and a significant permitting hurdle at its Penikat project in Finland. The company maintains a solid cash position as it plans for 2026 drilling campaigns.

Yugo Metals has made promising progress with diamond drilling at its Sinjakovo project, intersecting silver-zinc-lead mineralisation, while securing $3.5 million in new funding and expanding its investor reach through a dual listing in Germany.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.

Harvest Technology Group reports improved first-half FY26 financials alongside strategic defense sector expansions, including new reseller agreements and NATO engagements.

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Iondrive Limited has marked a pivotal shift from development to commercialisation of its IONSolv™ technology, securing $4 million to target the US e-waste market and commissioning its pilot plant to refine critical minerals.

BlinkLab Limited has delivered strong diagnostic results in its U.S. autism pilot study, exceeding FDA performance thresholds and setting the stage for a pivotal 510(k) trial. The company also expanded its clinical trial network and nears completion of its European ADHD study.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.